Skip to content
PaperFren

How does lactylation-driven ALKBH3 weaken tumor suppressors?

Open paper intelligence

Histone lactylation boosts ALKBH3, which removes m1A from SP100A and diminishes PML nuclear condensates, accelerating ocular melanoma progression.

Source

Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A

Gu X, Zhuang A, Yu J, et al. · Nucleic acids research · 2024

doi.org/10.1093/nar/gkad1193Read the full paper ↗121 citationscc by

What they did

Mapped ALKBH3 upregulation under high histone lactylation, identified SP100A as an ALKBH3 m1A target via multiomics, and tested silencing plus YTHDF1 recognition mechanisms in melanoma models.

What they found

ALKBH3 is upregulated in high-risk ocular melanoma with lactylation-linked m1A hypomethylation. Demethylating SP100A impairs PML body formation; ALKBH3 silencing has therapeutic efficacy that SP100A depletion can reverse. YTHDF1 recognizes methylated SP100A transcript.

The limits

What it doesn't show

Does not establish a ready-to-use clinical ALKBH3 inhibitor regimen; ocular melanoma findings may not transfer unchanged to all cancers.

Key terms

m1A
N1-methyladenosine RNA modification affecting RNA structure and protein interactions.
ALKBH3
m1A demethylase upregulated by histone lactylation in this study.
Histone lactylation
Metabolic stress-linked histone mark that boosts ALKBH3 expression here.
SP100A
PML-body component whose m1A status supports tumor-suppressive condensates.
PML condensates
Nuclear bodies with tumor-suppressor functions disrupted when SP100A is demethylated.
YTHDF1
Reader recognizing m1A-methylated SP100A transcript to stabilize/translate it.

Flashcards

1 / 8

Research intelligence for this paper

See its role on concept claims, tensions it is part of, placement history, and related discoveries.

Open paper intelligence

Quiz yourself

1 / 5

ALKBH3 expression is boosted by:

Common questions

What boosts ALKBH3?

Excessive histone lactylation in high-risk ocular melanoma.

Key downstream target?

SP100A, a core PML-body component.

Therapeutic hint?

Silencing ALKBH3 works in vitro/in vivo unless SP100A is depleted.

Who reads methylated SP100A?

YTHDF1.

More on Epigenetics